Literature DB >> 17541400

EBV-positive lymphoproliferative disease with medullary, splenic and hepatic infiltration after imatinib mesylate therapy for chronic myeloid leukemia.

T Leguay, C Foucaud, M Parrens, O Fitoussi, K Bouabdallah, M A Belaud-Rotureau, R Tabrizi, G Marit, A Pigneux, N Milpied.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17541400     DOI： 10.1038/sj.leu.2404758

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  3 in total

1.  Epstein-Barr virus-associated lymphoproliferative disease during imatinib mesylate treatment for chronic myeloid leukemia.

Authors:  Junko Yamaguchi; Takahiro Fujino; Reiko Isa; Daichi Nishiyama; Saeko Kuwahara-Ota; Yuka Kawaji; Taku Tsukamoto; Yoshiaki Chinen; Yuji Shimura; Tsutomu Kobayashi; Shigeo Horiike; Kei Kohno; Shigeo Nakamura; Junya Kuroda
Journal:  Haematologica       Date:  2019-04-11       Impact factor: 9.941

Review 2.  Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature.

Authors:  Bettina M Knoll; K Seiter
Journal:  Infection       Date:  2018-01-31       Impact factor: 3.553

3.  Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines.

Authors:  Hemant Kulkarni; Harald H H Göring; Vincent Diego; Shelley Cole; Ken R Walder; Greg R Collier; John Blangero; Melanie A Carless
Journal:  BMC Med Genomics       Date:  2012-08-23       Impact factor: 3.063
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.